n.a. (TSRX)

0.00
NASDAQ
Prev Close 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.00
Exchange NASDAQ
Shares Outstanding 48.27M
Div & Yield N.A. (N.A)

Latest News

Trius Therapeutics To Present Data From Antibiotics Development Programs At ICAAC 2013

Trius Therapeutics To Present Data From Antibiotics Development Programs At ICAAC 2013

Sessions Include Integrated Data From Phase 3 Studies of Trius' Experimental Drug Tedizolid as Well as Findings From Pre-Clinical Gram-Negative Program and cfr Resistance Studies

Cubist Announces Expiration Of Hart-Scott-Rodino Waiting Period For Acquisition Of Trius

Cubist Announces Expiration Of Hart-Scott-Rodino Waiting Period For Acquisition Of Trius

Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) and Trius Therapeutics, Inc.

Investigations Into Proposed Buyouts Of Optimer Pharmaceuticals, Inc., Trius Therapeutics, Inc. And Maidenform Brands, Inc. Announced By Holzer Holzer & Fistel, LLC

Investigations Into Proposed Buyouts Of Optimer Pharmaceuticals, Inc., Trius Therapeutics, Inc. And Maidenform Brands, Inc. Announced By Holzer Holzer & Fistel, LLC

Holzer Holzer & Fistel, LLC is investigating potential shareholder claims on behalf of investors who currently own Optimer Pharmaceuticals, Inc.

Faruqi & Faruqi, LLP, Partner Juan E. Monteverde Launches An Investigation Of Trius Therapeutics, Inc. Over The Proposed Sale Of The Company To Cubist Pharmaceuticals, Inc.

Faruqi & Faruqi, LLP, Partner Juan E. Monteverde Launches An Investigation Of Trius Therapeutics, Inc. Over The Proposed Sale Of The Company To Cubist Pharmaceuticals, Inc.

Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Trius Therapeutics (“Trius”...

Cramer's 'Mad Money' Recap: Disciplined Investors Rule

Cramer's 'Mad Money' Recap: Disciplined Investors Rule

You'll never make money just following the Federal Reserve, Cramer said.

The Deal: Cubist Commits $1.6B to Bolster Antibiotics Portfolio

The Deal: Cubist Commits $1.6B to Bolster Antibiotics Portfolio

Cubist Pharmaceuticals on Tuesday committed up to $1.6 billion to acquire two makers of next-generation antibiotics in a bid to expand aggressively its acute care product portfolio.

Finkelstein Thompson LLP Announces Investigation Of Trius Therapeutics, Inc. Buyout

Finkelstein Thompson LLP Announces Investigation Of Trius Therapeutics, Inc. Buyout

The law firm of Finkelstein Thompson LLP is investigating potential claims on behalf of shareholders of Trius Therapeutics, Inc.

Cramer Quick Take: What's Next for Biotech?

Cramer Quick Take: What's Next for Biotech?

Jim Cramer looks at the implications of the latest biotech deal, Cubist acquiring Trius, and the implications for the biotech sector.

Trius Shareholder Alert: The Briscoe Law Firm And Powers Taylor, LLP Investigate Sale Of Trius To Cubist

Trius Shareholder Alert: The Briscoe Law Firm And Powers Taylor, LLP Investigate Sale Of Trius To Cubist

Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor, LLP are investigating the sale of Trius Therapeutics, Inc.

Morning Briefing: 10 Things You Should Know

Morning Briefing: 10 Things You Should Know

U.S. stock futures suggest a flat to slightly higher start for Wall Street; Cubist Pharmaceuticals makes two acquisitions; MasterCard and Comcast highlight the earnings calendar.

Cubist Becomes Dominant Antibiotic Seller With Optimer, Trius Buys

Cubist Becomes Dominant Antibiotic Seller With Optimer, Trius Buys

Cubist announces two acquisitions in one day.

Cubist Pharmaceuticals To Acquire Trius Therapeutics

Cubist Pharmaceuticals To Acquire Trius Therapeutics

Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) and Trius Therapeutics, Inc.

First Week Of March 2014 Options Trading For Trius Therapeutics (TSRX)

First Week Of March 2014 Options Trading For Trius Therapeutics (TSRX)

Investors in Trius Therapeutics Inc. saw new options begin trading this week, for the March 2014 expiration.

Cramer's Top Stock Picks: FDO DG FIVE TSRX

Cramer's Top Stock Picks: FDO DG FIVE TSRX

Five Below is Cramer's favorite dollar store and Trius Therapeutics is a biotech to watch.

Cramer's 'Mad Money' Recap: Stocks Still Make Sense

Cramer's 'Mad Money' Recap: Stocks Still Make Sense

With stocks back on the front page, there are plenty of profits yet to be made, Cramer said.

TSRX, CYTK, ARRY: 3 Stocks on TV

TSRX, CYTK, ARRY: 3 Stocks on TV

StockMarketMentor.com founder Dan Fitzpatrick details how to play three stocks Jim Cramer discussed on CNBC's "Mad Money" last night.

Cramer's 'Mad Money' Recap: Ignore the Headlines

Cramer's 'Mad Money' Recap: Ignore the Headlines

The stock market is doing better than investors think, Cramer asserts.

Trius Therapeutics Announces Publication Of Antibiotic Safety Study In Antimicrobial Agents And Chemotherapy

Trius Therapeutics Announces Publication Of Antibiotic Safety Study In Antimicrobial Agents And Chemotherapy

Peer-Reviewed Results Suggest No Clinically Significant Interactions Between Trius' Experimental Antibiotic Tedizolid and a Commonly Used Class of Medications

Commit To Buy Trius Therapeutics At $5, Earn 11.1% Annualized

Commit To Buy Trius Therapeutics At $5, Earn 11.1% Annualized

Investors considering a purchase of Trius Therapeutics Inc. shares, but cautious about paying the going market price of $7.92/share, might benefit from considering selling puts among the alternative strategies at their disposal.

Trius Appoints Matthew Onaitis As General Counsel

Trius Appoints Matthew Onaitis As General Counsel

Industry Veteran Brings Legal, Transactional and Commercial Compliance Expertise